ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 451

The Association of Fine Specificities of Anti-Citrullinated Protein Antibodies (ACPA) with  disease Severity  in African-Americans with RA

Maria I. Danila1, Richard Reynolds2, Gordon Wu3, Hemant Tiwari3, William H. Robinson4, Jeremy Sokolove5, CLEAR Investigators2 and S. Louis Bridges Jr.2,6, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Biostatistics, University of Alabama at Birmingham, Birmingham, AL, 4VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 5VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, 6Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), joint damage and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: RA is characterized by the presence of autoantibodies to citrullinated proteins (ACPA) and joint damage. The role of fine specificities of ACPA in radiographic severity has not been defined. The purpose of the current study was to evaluate whether fine specificities of ACPA are associated with radiographic severity of RA in African Americans.

Methods: Using a custom Bio-Plex™ bead-based autoantibody assay platform, we measured anti-CCP antibody and 19 autoantibodies  targeting citrullinated proteins and peptides (vimentin, fibrinogen, histone 2A , histone 2B, and apolipoprotein E, clusterin, biglycan, enolase, fillagrin).  We analyzed sera from 692 African-American patients with RA. A total antibody score was defined for each patient as the  standardized sum of the log transformed autoantibodies . The total antibody score was used as predictor variable for radiographic severity. Radiographic severity defined as total Sharp/van der Heijde scores of hands/feet was the dependent variable.  Zero-inflated negative binomial regression models were used to test the association of the autoantibody score with radiographic severity defined as total Sharp/van der Heijde scores of hands/feet given the covariates gender, BMI, smoking status and disease duration.

Results: High correlation coefficients among the autoantibodies were observed.  Using zero-inflated negative binomial regression, the total sum of standardized antibodies had a statistical significant (p-value =0.002) effect among patients with a total RA radiographic severity (total score >0). For each unit increase in the total sum of standardized autoantibodies, the total radiographic score increases by 0.3 units. In addition, disease duration was found to be statistically significant (p-value <0.0001).

Conclusion: Autoantibodies against citrullinated autoantigens are associated with joint damage in this cross sectional study of African Americans with RA. Future work will focus on longitudinal aspects of antibodies to specific peptides/proteins and their role in progression of radiographic damage.


Disclosure:

M. I. Danila,
None;

R. Reynolds,
None;

G. Wu,
None;

H. Tiwari,
None;

W. H. Robinson,
None;

J. Sokolove,
None;

C. Investigators,
None;

S. L. Bridges Jr.,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-of-fine-specificities-of-anti-citrullinated-protein-antibodies-acpa-with-disease-severity-in-african-americans-with-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology